Study of blood particles as markers for liver disease
Part of Cancer, Digestive system clinical trials.
This trial looks at tiny particles in the blood (extracellular vesicles) to see if they can help doctors understand and track liver disease. It includes healthy volunteers, people with diabetes and liver scarring, and people with cirrhosis, with the goal of finding better biomarkers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You can join as a healthy volunteer with no known liver disease, as a patient with diabetes and liver scarring, or as a patient with cirrhosis.
- If you are diabetic, you need to have significant liver scarring (stage F3/F4) confirmed by a biopsy or an elasticity scan showing a result above 10 kPa.
- If you have liver disease, you need to have cirrhosis diagnosed by biopsy, an elasticity scan above 15 kPa, or other clinical signs.
- You must not have active cancer, a recent infection, or have received a blood transfusion in the past month.
- You cannot be pregnant or breastfeeding, and you must not have participated in another interventional trial in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
This study is testing a new way to use a FibroScan (a non-invasive liver scanner) with a single probe to measure liver health in people with chronic liver disease. If you have a long-term liver condition, this trial may help improve how liver exams are done.
This study looks at how blood clotting, inflammation, and blood vessels change in people with chronic liver disease or cirrhosis. Your blood tests may help researchers understand what drives the disease and could guide future care.
This trial screens for liver scarring (fibrosis) or severe scarring (cirrhosis) caused by hepatitis B or C. It aims to find people who may benefit from further care or treatment.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.